Carbapenemase Gene Transmission in Enterobacter cloacae: Technical Insights from Guangdong Province (2022–2024)

Study Background and Research Question

The global emergence of carbapenem-resistant Enterobacteriaceae (CRE) represents a major threat to public health, with Enterobacter cloacae (CREC) ranking among the top three CRE pathogens in China. The COVID-19 pandemic further complicated the landscape, intensifying antibiotic selective pressures and disrupting hospital infection control. Despite the clinical significance, the detailed transmission dynamics and molecular characterization of carbapenemase-encoding genes (CEGs) in CREC, particularly in the context of pandemic-driven healthcare changes, have remained incompletely understood (Chen et al., 2025).

Key Innovation from the Reference Study

Chen et al. provide a granular, multicenter analysis of 54 CREC isolates collected from eight teaching hospitals in Guangdong, China, spanning December 2022 to June 2024. By integrating molecular genotyping, plasmid profiling, and transmission dynamics, the study delivers a nuanced understanding of how CEGs—especially blaNDM−1—propagate in the clinical environment. The work is distinguished by its focus on both chromosomal and plasmid localization of resistance genes, as well as its quantification of horizontal gene transfer efficiency—an aspect often presumed but rarely measured directly in clinical isolates (Chen et al., 2025).

Methods and Experimental Design Insights

The investigators collected 54 non-duplicate CREC isolates from eight tertiary teaching hospitals. The study applied a combination of variable temperature Sodium Dodecyl Sulfate (SDS) plasmid elimination and PCR to detect the presence and localization of key CEGs (notably blaNDM−1, blaIMP, blaKPC−2). Resistance phenotypes were assessed using the broth microdilution method, while plasmid conjugation experiments were performed to quantify horizontal transfer rates. Mobile genetic elements were cataloged, and ERIC-PCR, coupled with NTSYS software, enabled genotype clustering and epidemiological mapping across hospital departments and patient demographics (Chen et al., 2025).

Protocol Parameters

• Plasmid elimination assay | variable temperature SDS method | CEG localization | Enables discrimination between chromosomal and plasmid-borne genes | paper
• Resistance testing | broth microdilution | MDR phenotype comparison | Quantifies resistance differences between CEG-positive and CEG-negative strains | paper
• Plasmid conjugation | filter mating, PCR validation | horizontal gene transfer | Measures efficiency of CEG transfer among isolates | paper
• Genotyping | ERIC-PCR, NTSYS clustering | epidemiological mapping | Identifies dominant genotypes and tracks inter-hospital spread | paper

Core Findings and Why They Matter

The study reports an 85.19% positive rate for CEGs among CREC isolates, with blaNDM−1 being the most frequent gene, often localized on plasmids (46.30%) or both plasmids and chromosomes (33.33%). Less common were blaIMP (3.70%) and co-occurrence of blaNDM−1 and blaKPC−2 (1.85%). Notably, the resistance rates in CEG-positive isolates were significantly higher for imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin compared to CEG-negative isolates (source: Chen et al., 2025). Plasmid conjugation experiments yielded a 95.65% success rate for CEG transfer, with blaNDM−1 and blaIMP showing near-complete transferability (95.45% and 100%, respectively). Six mobile genetic elements were identified, with ISEcp1 being present in 87.04% of isolates. The most prevalent scenario (40.74%) was the presence of four mobile genetic elements within a single isolate, suggesting a high potential for gene mobility and recombination (source: Chen et al., 2025). Genotyping revealed 17 distinct types, with types E and G each accounting for over 20% of isolates and being distributed across multiple hospitals and departments. Epidemiologically, higher CEG detection rates were observed in male and elderly patients, particularly in respiratory medicine and from sputum samples (64.81% males, 72.22% elderly, 20.37% respiratory medicine, 33.33% sputum) (Chen et al., 2025).

Comparison with Existing Internal Articles

Several internal resources contextualize CEG-mediated resistance within the broader spectrum of Gram-negative infection research and experimental strategy. For instance, "Ceftazidime: Mechanistic Insight and Translational Impact" discusses ceftazidime’s value as a third-generation cephalosporin and its deployment in research focused on multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa. This aligns with the reference study’s emphasis on the challenge posed by β-lactamase-producing strains and the need for robust agents in both treatment and laboratory investigation (source: internal_article). Further, "Ceftazidime: Broad-Spectrum Third-Generation Cephalosporin" highlights the antibiotic’s β-lactamase resistance and utility in respiratory infection models, complementing the epidemiological findings in Chen et al. regarding the predominance of CREC in respiratory departments. These articles together underscore the translational imperative for integrating resistance surveillance with experimental design in Gram-negative bacterial infection research (source: internal_article).

Limitations and Transferability

While Chen et al. deliver a comprehensive multicenter snapshot, several limitations warrant consideration. The study is geographically constrained to Guangdong and may not capture the full diversity of CREC genotypes or resistance mechanisms seen in other regions. Sampling was limited to eight hospitals and a specific timeframe (pandemic/post-pandemic), introducing potential bias from local outbreak dynamics. Moreover, while conjugation assays confirm high transferability of CEGs, their in vivo transfer dynamics under clinical conditions remain to be fully elucidated (Chen et al., 2025). The findings are highly relevant for researchers developing new protocols for the treatment of bacterial pneumonia, bronchitis, and other respiratory infections caused by multidrug-resistant Gram-negative organisms, but direct clinical translation requires context-specific validation.

Research Support Resources

For laboratories seeking to replicate or extend such resistance surveillance or treatment studies, the use of molecularly robust, β-lactamase-resistant antibiotics is critical. Researchers can source Ceftazidime (SKU B3539), a third-generation cephalosporin with proven efficacy against Gram-negative pathogens including Pseudomonas aeruginosa and β-lactamase-producing Enterobacteriaceae, from APExBIO to support experimental workflows in Gram-negative bacterial infection research (source: product_spec). For best practices in antibiotic application and resistance monitoring, users may refer to the protocols and recommendations outlined in the internal article “Ceftazidime (SKU B3539): Reliable Solutions for Gram-Negative Infection Research”.